Results 111 to 120 of about 45,032 (221)

The Dual Role of the Gut Microbiota in Cancer Chemoresistance

MicrobiologyOpen, Volume 15, Issue 4, August 2026.
Comparison between Microbiota and Cancer therapy. ABSTRACT Chemoresistance is one of the primary reasons that cancer chemotherapy fails to deliver successful treatment outcomes and contributes to poor overall survival rates for patients with cancer. New research has begun to shed light on the effects of the gut microbiome (GM).
Hamed Tahmasebi, Aisa Bahar, Meisam Khazaei, Mohammad Reza Arabestani   +3 more
wiley   +1 more source

Development of an adult whole-body PBPK model of irinotecan and its metabolites for predicting UGT1A1/CYP3A-mediated drug-drug interactions. [PDF]

Front Pharmacol
Chen B, Li L, Xu W, Xu H, Zhu X, He Q, Zhu X, Chi-Lui Ho P, Xiang X, Ji P.   +9 more
europepmc   +1 more source

Deep Learning Predicts Imminent Tumor Progression in Advanced Pancreatic Adenocarcinoma Using Serial CT Scans During Chemotherapy

MedComm, Volume 7, Issue 8, August 2026.
A spatiotemporal deep learning model combining serial CT scans and baseline clinical data predicts tumor progression at the next follow‐up visit in advanced PDAC. The model achieved robust performance across internal, external, and prospective cohorts (AUC: 0.74–0.77). This noninvasive approach enables earlier identification of imminent progression and
Jun Cheng, Yize Mao, Shuxiang Huang, Xiaotong Tan, Xiaoping Yi, Xiaoying Du, Qiulin Liu, Jianyao Zhou, Rong Huang, Weijie Chen, Rong Zhang, Lizhi Liu, Wufeng Xue, Ruobing Huang, Youhui Qian, Dong Ni, Wenjun Mao, Tao Qin, Shengping Li, Qiuxia Yang   +19 more
wiley   +1 more source

Impact of <i>UGT1A1*28</i> polymorphism in patients with metastatic pancreatic ductal adenocarcinoma treated with NALIRIFOX in the NAPOLI 3 trial. [PDF]

Future Oncol
Abdelrahim M, Khan G, Hatoum H, Zervoudakis A, Dayyani F, Zhang L, Li J, Maxwell F, O'Reilly EM, Wainberg ZA, Bullock A.   +10 more
europepmc   +1 more source

Antibody–Drug Conjugates and Peptide–Drug Conjugates: Current Understandings and Future Perspectives

MedComm, Volume 7, Issue 8, August 2026.
The graphic summarizes the design principles, intracellular trafficking, clinical progress, challenges, and future directions of antibody–drug conjugates (ADCs) and peptide–drug conjugates (PDCs). ADCs consist of a tumor‐targeting antibody, a chemical linker, and a potent payload, whereas PDCs use peptide ligands to deliver cytotoxic, radionuclide, or ...
Ruxi Zheng, Shuiquan Li, Zhigang Zhang, Mengke Niu, Jing Fei, Jiaojiao Zhang, Jianwei Zhou, Kongming Wu, Ming Yi, Tianye Li   +9 more
wiley   +1 more source

Long-term survival in metastatic abdominal Ewing sarcoma with gastric serosal involvement following first-line irinotecan plus cisplatin: a case report. [PDF]

Front Oncol
Ji L, Li Y, Chen X, Liu Y, Tao W, Wang G, Cui T, Chen Y, Sun H, Jiang N, Wang K.   +10 more
europepmc   +1 more source

Reactive Cutaneous Capillary Endothelial Proliferation in Esophageal Squamous Cell Carcinoma Patients Treated With Camrelizumab‐Based Therapy: A Pooled Analysis of Two Phase 3 Trials

MedComm, Volume 7, Issue 8, August 2026.
Camrelizumab‐induced reactive cutaneous capillary endothelial proliferation (RCCEP) was frequent yet manageable in patients with advanced esophageal squamous cell carcinoma and correlated with improved response and survival, suggesting RCCEP as a potential on‐treatment biomarker of clinical benefit.
Jia Liu, Ye He, Mingming He, Fan Chen, Zhiguo Hou, Zhaoqing Zheng, Chaoyu Lin, Aichun Chen, Ruihua Xu, Huiyan Luo, ESCORT‐1st Study Group, ESCORT Study Group   +11 more
wiley   +1 more source

Enzymatic Laccase Nanoreactors Induce Apoptosis in MOLT-4-ALL Cells and Activate Prodrugs in a Synergetic Effect. [PDF]

Blood Lymphat Cancer
Medrano-Villagómez CA, Loredo-García E, Gasperin-Bulbarela J, Vazquez-Duhalt R.   +3 more
europepmc   +1 more source

Addressing the distressing: Pancreatic enzyme replacement therapy mitigates abdominal symptoms and weight loss during chemotherapy for advanced pancreatic cancer: A prospective study

Nutrition in Clinical Practice, Volume 41, Issue 4, Page 1157-1165, August 2026.
Abstract Background Pancreatic enzyme insufficiency (PEI) contributes to symptom burden and malnutrition in advanced pancreatic cancer (aPC). We aimed to evaluate the impact of pancreatic enzyme replacement therapy (PERT) on symptom burden and weight during chemotherapy.
Pamela N. Klassen, Christina A. Kim, Jessica Kasnik, Michael B. Sawyer, Sunita Ghosh, Vickie Baracos, Vera C. Mazurak   +6 more
wiley   +1 more source

Association Between Irinotecan-Containing Regimens and Functional and Nutritional Impairment in Advanced Colorectal Cancer: An Exploratory PG-SGA Analysis. [PDF]

Cancers (Basel)
Guerrero-Martín J, Macias-Montero R, Macías-Gañán Y, Araujo-Blesa M, Paniagua-Vivas MS, Sánchez-Diestro LE.   +5 more
europepmc   +1 more source